Mettler-Toledo Beats Expectations on China Rebound, Raises Full-Year Outlook
The Swiss precision instruments maker posted 4% organic growth in Q2 and lifted its 2026 EPS guidance, citing improved market conditions in China and emerging markets.
Strong Quarter Exceeds Guidance
Mettler-Toledo International Inc. reported second-quarter results that significantly exceeded its prior guidance, driven by better-than-expected organic sales growth across its portfolio. The company posted local currency sales growth of 6%, well above its previous forecast of approximately 3%, with organic growth reaching 4% (earnings call, 2026-07-31).
Adjusted earnings per share climbed 14% to $11.46, reflecting both revenue momentum and margin expansion. Adjusted operating margin improved 50 basis points to 29.3%, or 100 basis points excluding currency headwinds, as the company benefited from favorable pricing, lower tariff rates, and productivity initiatives (earnings call, 2026-07-31).
China and Emerging Markets Drive Performance
The standout performance came from Asia and emerging markets. China delivered 9% organic growth, a significant acceleration that CEO Patrick Kaltenbach attributed to the team's "excellent job identifying high-growth markets and leveraging our innovative portfolio" (earnings call, 2026-07-31). The broader Asia/Rest of World region posted 9% organic growth.
Emerging markets outside China, representing approximately 18% of total sales—slightly more than China itself—grew at a high single-digit rate. These markets have maintained high single-digit average growth over the past five years, positioning them as increasingly important growth contributors (earnings call, 2026-07-31).
Europe delivered solid 4% organic growth, while the Americas posted more modest 1% growth, with strength in laboratory products and core industrial automation offset by timing issues in food retail and transportation projects.
Product Portfolio Shows Broad Strength
The laboratory segment, Mettler-Toledo's largest division, achieved good growth across most product areas. The company saw improving trends in its biopharma customer base and continued strength in process analytics and bioproduction. Laboratory balances and analytical instruments benefited from recent innovations, the company's LabX software platform, and growing demand from semiconductor, advanced materials, and battery manufacturing segments (earnings call, 2026-07-31).
Core industrial products grew 4%, driven by automation solutions serving biopharma, food manufacturing, semiconductor, and new energy markets. Service revenue, a high-margin recurring business, grew 7% organically (earnings call, 2026-07-31).
Upgraded Outlook Reflects Confidence
Based on the strong quarter and improved market conditions, Mettler-Toledo raised its full-year 2026 guidance. The company now expects local currency sales growth of 4% to 5%, up from its previous 4% forecast, with organic growth of 3% to 4%. Adjusted EPS guidance increased to a range of $47.15 to $47.50, representing 10% to 11% growth, or 11% to 12% excluding currency—an increase from the prior 8% to 10% growth forecast (earnings call, 2026-07-31).
CFO Shawn Vadala noted the company is "very confident in our ability to execute on our growth and productivity initiatives and believe we are well positioned to gain market share regardless of the macro environment" (earnings call, 2026-07-31).
The company also increased its share repurchase program to $875 million for the full year, up from an $825 million annualized rate in the first half, while maintaining its free cash flow guidance of approximately $900 million (earnings call, 2026-07-31).
This article was generated by MarginX from the earnings call on 2026-07-31. It is not investment advice.